Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.
CVRx announced first-patient enrollment in the BENEFIT-HF trial, a 2,500-patient heart failure study across about 150 U.S. and German centers. The trial will evaluate all-cause mortality and heart failure decompensation events through 2032.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07707583 |
Heart Rate Variability and Medication Adherence in Resistant Hypertension |
NOT_YET_RECRUITING | |
| NCT07635914 |
A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension |
NOT_YET_RECRUITING | PHASE3 |
| NCT06526858 |
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension |
RECRUITING | NA |
| NCT06216808 |
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension |
ACTIVE_NOT_RECRUITING | NA |
| NCT06168409 |
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension |
COMPLETED | PHASE3 |
| NCT06034743 |
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension |
COMPLETED | PHASE3 |
| NCT05888233 |
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension |
ACTIVE_NOT_RECRUITING | PHASE2 |
